Waiting times between examinations with intravascularly administered contrast media: a review of contrast media pharmacokinetics and updated ESUR Contrast Media Safety Committee guidelines
Authors:
- Aart J van der MolenAMAart J van der Molen
- Ilona A DekkersIDIlona A Dekkers
- Remy W F GeenenRGRemy W F Geenen
- Marie-France BellinMBMarie-France Bellin
- Michele BertolottoMBMichele Bertolotto
- Torkel B BrismarTBTorkel B Brismar
- Jean-Michel CorreasJCJean-Michel Correas
- Gertraud Heinz-PeerGHGertraud Heinz-Peer
- Andreas H MahnkenAMAndreas H Mahnken
- Carlo C QuattrocchiCQCarlo C Quattrocchi
- Alexander RadbruchARAlexander Radbruch
- Peter ReimerPRPeter Reimer
Open Access
- 12 October 2023
- journal article
- review article
- Published by Springer Nature in European Radiology
- Vol. 34 (4) , 2512-2523
Abstract
The pharmacokinetics of contrast media (CM) will determine how long safe waiting intervals between successive CT or MRI examinations should be. The Contrast Media Safety Committee has reviewed the data on pharmacokinetics of contrast media to suggest safe waiting intervals between successive contrast-enhanced imaging studies in relation to the renal function of the patient. Clinical relevance statement: Consider a waiting time between elective contrast-enhanced CT and (coronary) angiography with successive iodine-based contrast media administrations in patients with normal renal function (eGFR > 60 mL/min/1.73 m2) of optimally 12 h (near complete clearance of the previously administered iodine-based contrast media) and minimally 4 h (if clinical indication requires rapid follow-up). Key Points: • Pharmacokinetics of contrast media will guide safe waiting times between successive administrations. • Safe waiting times increase with increasing renal insufficiency. • Iodine-based contrast media influence MRI signal intensities and gadolinium-based contrast agents influence CT attenuation.Keywords
This publication has 92 references indexed in Scilit:
- Optimization of the Contrast Mixture Ratio for Simultaneous Direct MR and CT Arthrography: an in Vitro StudyKorean Journal of Radiology, 2008
- Quantitative evaluation of the relaxivity effects of iodine on GD‐DTPA enhanced MR arthrographyJournal of Magnetic Resonance Imaging, 2007
- An Overview of the Clinical Pharmacokinetics of X-Ray Contrast MediaClinical Pharmacokinetics, 1997
- IodixanolDrugs, 1996
- Gadodiamid und Gadolinium-DTPA als intravenöse Kontrastmittel in der ComputertomographieRöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 1996
- Whole Body Quantitative Autoradiographic Study of the Biodistribution of Iobitridol in RatsInvestigative Radiology, 1994
- Preclinical Safety Assessment and Pharmacokinetics of Gadodiamide Injection, a New Magnetic Resonance Imaging Contrast AgentInvestigative Radiology, 1993
- A Phase I Clinical Trial with Gadodiamide Injection, a Nonionic Magnetic Resonance Imaging Enhancement AgentInvestigative Radiology, 1991
- Biodistribution and Excretion of 125I Ioversol in Conscious DogsInvestigative Radiology, 1989
- Pharmacokinetics of lodamide in Normal Subjects and in Patients with Renal ImpairmentThe Journal of Clinical Pharmacology, 1977